Effect of Combined Immune Checkpoint Inhibition vs Best Supportive Care Alone in Patients With Advanced Colorectal Cancer

Abstract

Importance: Single-agent immune checkpoint inhibition has not shown activities in advanced refractory colorectal cancer (CRC), other than in those patients who are microsatellite-instability high (MSI-H). Objective: To evaluate whether combining programmed death-ligand 1 (PD-L1) and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) inhibition improved patient survival in metastatic refractory CRC.

Authors

Chen EX; Jonker DJ; Loree JM; Kennecke HF; Berry SR; Couture F; Ahmad CE; Goffin JR; Kavan P; Harb M

Journal

JAMA Oncology, Vol. 6, No. 6, pp. 831–838

Publisher

American Medical Association (AMA)

Publication Date

June 1, 2020

DOI

10.1001/jamaoncol.2020.0910

ISSN

2374-2437

Associated Experts

John Goffin

Associate Professor, Faculty of Health Sciences

Visit profile

Labels